Ois Podcast

On this week’s episode of the OIS Podcast, Robert Rothman, MD, is joined by Vince Anido, Chairman and CEO of Aerie Pharmaceuticals. Vince shares his vision for Aerie, and how his lean, efficient team carefully strategizes every move they make to cultivate products that benefit patients. We learn background on both Vince and Aerie, and how two of Aerie’s products, Rhopressa and Rocklatane, were brought to market in under one year. How has Aerie has made a name for themselves globally within glaucoma, and next in dry eye, and retina?

On this week’s episode of the OIS Podcast, Firas Rahhal, MD, is joined by Calvin Roberts, MD, CEO of Lighthouse Guild. Cal has over 36 years under his belt in the eye care sector ranging from academia, private practice, and industry. He shares the positive and the negative of transitioning from a private practice on Park Ave over to being the Chief Medical Officer of Bausch + Lomb. Listen in for important factors to consider such as autonomy, security, and the impact on those around you when considering the leap over to industry. We’ll also learn how Cal is weaving his previous experiences into the work he is doing for Lighthouse Guild and how they strive to reduce the burdens of vision loss for patients.

This week on the OIS Podcast, Paul Karpecki, OD, FAAO, speaks with the new CEO of TearClear, Robert Dempsey, to uncover what has been necessary for him to succeed in the space. Listen in as Robert discusses the importance of assembling a trustworthy crew before zeroing in on goals and objectives. Learn how his professional experiences have helped him build out a unique Medical Advisory Board for TearClear comprised of 50% optometry and 50% ophthalmology and what the future of TearClear looks like. Press play now and learn from one of the best!

We have a great conversation for you this week on the OIS Podcast: Paul Karpecki, OD, FAAO, joins Kim Brazzell, PhD and Chief Medical Officer at Kala Pharmaceuticals, to discuss Kim’s experience developing EYSUVIS, the first FDA-approved prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease.Kim gives us tips for navigating the approval process and shares lessons learned since he started working in the space. You don’t want to miss this episode. Press play now!

This week on the OIS podcast, we have an exciting conversation between Ehsan Sadri, M.D. and Shervin Korangy, President and CEO of BVI Medical.Listen in as Shervin shares highlights of his professional evolution. He tells us how his unique path of living overseas and working on Wall Street has impacted how he thinks about building and managing teams, and how the impact extends to planning the next steps for BVI. His perspective is innovative, refreshing, and not to be missed!Would you like to be featured on our podcast? Visit OIS.net and click Get Involved to submit your information.

This week on the OIS podcast, Dr. William Link of Flying L. Partners leads a fantastic panel featuring five successful Ophthalmic investors who share the important lessons 2020 bestowed on the industry that can help you build out your 2021 portfolio. Special thanks to: Arjun Arora, Director, KKR; Ali Behbahani, MD, General Partner, NEA; Anat Naschitz, Managing Director, OrbiMed; Bruce Robertson, Managing Director, H.I.G. Capital; and Jeffry Weinhuff, Managing Partner, Visionary Venture Fund for sharing their insight and for spending time with us.Press play now and listen in on this innovative conversation!

This week OIS is “ExSighted” to bring you a candid conversation with the dynamic trio that formed ExSight Venturess: Our host, Dr. Firas Rahhal, is joined by his partners Dr. Michael Nissen, and James Murray, JD. to describe why two practicing physicians and a lawyer decided to launch a specialized fund focused on investing in early-stage ophthalmology start-ups. The group also talks about their investment strategy, existing portfolio, and where they see the market heading.

OIS Podcast host Firas Rahhal, MD, of ExSight Ventures and Retina Vitreous Associates sits down with not one but two members of Outlook Therapeutics’ C-Suite staff, Terry Dagnon and Jeff Evanson. We learn about what kind of collaborations and strategies are necessary behind the scenes at Outlook and learn more about the company’s road to bringing ONS-5010/Lytenava (bevacizumab-vikg) – potentially the only Food and Drug Administration-approved form of bevacizumab for the eye – to market. From studies, dosing, pricing, and other considerations, they cover it all. Press play now and listen in on this innovative conversation!

This week on the OIS podcast, Paul Karpecki, OD, FAAO of Kentucky Eye Institute sits down with Jerry St. Peter, Co-Founder, CEO, and Director of Eyevance. Together they take a look back at Jerry’s impactful career in Ophthalmology. Jerry shares pearls of wisdom around building businesses, wading through acquisitions, and talks about the importance of surrounding yourself with quality people to stay on the road to success. There’s something for everyone in this conversation- press play now!

This week on the OIS podcast, host Firas Rahhal, MD, Partner at ExSight Ventures & Retina Vitreous Associates Medical Group facilitates an illuminating discussion on the topic of retina start-ups with a focus on providing tips to anyone interested in joining the retina space.  Our guests include Andrew Stewart, AVP, US Commercial Retina of Allergan; Jay Duker, MD, Chief Strategic Scientific Officer, EyePoint Pharmaceuticals; Paul Hallen, VP & Global Head, Retina & Glaucoma, Alcon; and Ram Palanki, PharmD, SVP, Commercial Strategy & Operations, REGENXBIO.Listen in as this group shares advice on the topics of talent, asset quality, company strategies, and product development across the board. Learn what companies are looking for and where there is room for start-ups to flourish!

This week we’re bringing you a unique discussion that marries investments in Life Sciences and the field of Ophthalmology! Our host Firas Rahal, MD and guests Rob Rothman, MD and Ron Weiss, MD connect on this episode to discuss how two areas of interest converge in a symbiotic relationship that helps keep innovation at the forefront of Ophthalmology.

This week the OIS podcast touches on several topics within the realm of Glaucoma. We’re pleased to bring you this fascinating conversation hosted by Dr. Ehsan Sadri featuring guests Ike Ahmed, MD; Janet Serle, MD; Paul Singh, MD.This conversation covers proactive diagnostic technologies, approaches to both traditional and innovative therapies, and advancements that have defined the Glaucoma sector of medicine as we know it. Listen in to hear thoughts on cutting-edge solutions such as gene therapy and MIGS that hold the potential to help specialists manage both progressed and new patients.

This week we veer off the beaten path to bring you a unique panel discussion with industry leaders from Allergan, Santen, Genentech, and Aerie Pharmaceuticals. Each share expertise on drug development technologies and discusses insights on some of the hurdles they have had to overcome to successfully roll out products in pharma.

This week the OIS podcast brings you a thoughtful conversation with host Dr. Emmett Cunningham and guest Daphne Haim-Langford, PhD, Founder & CEO of Tarsius Pharma. Daphne takes us through her 20+ years in the Ophthalmology industry, complete with details about her latest clinical trials to tackle uveitis, the third leading cause of blindness.

This week we shift gears back to “R” for the OIS Retina Podcast with Dr Firas Rahhal and his esteemed guest Dr Steven Schwartz who raises the bar as a physician, an educator and of course an innovator. Steve shares his unlikely path into ophthalmology and how serendipity or luck surrounded him with great people which led to great opportunities. Steve shares an entertaining look at his career, the many start-ups that he’s had a hand in and the future of surgical robotics. If there’s one episode you want to listen to – this is it. 

This week’s guest is a Harvard-trained physician-scientist, inventor, entrepreneur, and serial innovator. The one and only Sean Ianchulev shares his story as an emigrant of communist Bulgaria who overcame many obstacles to become one of the top innovators in the field of ophthalmology. We learn why he committed to the uncertain winding path of innovation over the straight-line physician career/clinical practice. Early formative projects on digital diagnostics with the first virtual device for online perimetry and intra-operative aberrometry and understanding the role of industry/capital in taking R&D and discovery out of “neutral” and into over-drive to bring it to patients and physicians. And don’t forget about Eyenovia’s breakthrough technology for smart micro-therapeutics and the possibility to solve the global problems of progressive myopia and presbyopia...telemedicine and vision without boundaries...and innovation for global outreach and disease treatment. How he plans to change the equation of tric

In this wide-ranging discussion, Dr. Joe Boorady shares his perspective on the state of ophthalmic care today, his experience transforming powerful ideas into high-impact realities, and the spark that lights his entrepreneurial fire. Interviewed by Paul Karpecki, OD, this week’s conversation is one you won’t want to miss.

On this week’s OIS Retina podcast, we have the privilege of talking to Steve Pakola, MD. Steve is an industry veteran who has held key leadership roles in preclinical and clinical development, regulatory affairs, and medical affairs. Currently, he serves as Chief Medical Officer at REGENXBIO, a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

With a medical career spanning 35 years, including as global head of immunology at Sandoz (now Novartis), Patrik De Haes, MD, has cultivated deep experience turning scientific ambition into life-changing reality. In this unmissable episode, we talk to Dr. De Haes, now CEO of Brussels-based Oxurion, to get a deeper look at the business, research, and cultural elements that drive a product’s journey from concept to commercial.

This week the OIS Podcast hits a milestone with Episode 250. To mark the occasion, we feature a discussion with Tim Clover from the recent OIS European Innovation Showcase. Tim talks about his journey with Rayner and some significant changes he’s made since joining in 2014.  Listen in (or watch) to learn more about Tim and his vision for Rayner’s expansion as a dominant player in eye-care.